AR081261A1 - Metodos para tratar afecciones virales - Google Patents
Metodos para tratar afecciones viralesInfo
- Publication number
- AR081261A1 AR081261A1 ARP110101835A ARP110101835A AR081261A1 AR 081261 A1 AR081261 A1 AR 081261A1 AR P110101835 A ARP110101835 A AR P110101835A AR P110101835 A ARP110101835 A AR P110101835A AR 081261 A1 AR081261 A1 AR 081261A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- hydrogen
- hydroxyl
- compounds
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 230000003612 virological effect Effects 0.000 title 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 9
- 239000001257 hydrogen Substances 0.000 abstract 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- 125000003107 substituted aryl group Chemical group 0.000 abstract 5
- 229910052736 halogen Chemical group 0.000 abstract 4
- 150000002367 halogens Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 108020005202 Viral DNA Proteins 0.000 abstract 2
- 108010067390 Viral Proteins Proteins 0.000 abstract 2
- 108020000999 Viral RNA Proteins 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 230000000120 cytopathologic effect Effects 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 230000029812 viral genome replication Effects 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 abstract 1
- 238000011374 additional therapy Methods 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000009097 single-agent therapy Methods 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 150000003568 thioethers Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuestos que inhiben en forma selectiva la replicación viral o la producción del ARN o ADN viral. la proteína viral o los efectos citopáticos inducidos por el virus y las composiciones que comprenden estos compuestos. Métodos para inhibir la replicación viral o la producción de ARN o ADN viral, la proteína viral o los efectos citopáticos inducidos por el virus utilizando estos compuestos y los métodos para tratar infecciones virales que involucran la administración de estos compuestos. Los compuestos se pueden administrar en forma de terapia de un único agente o en combinación con una o más terapias adicionales a un humano que necesita de este tratamiento. Reivindicación 1: Un método para tratar una infección viral en un humano que lo necesita caracterizado porque comprende la administración al humano de una cantidad eficaz de un compuesto que tiene la fórmula (1), o su sal, racemato, tautómero o estereoisómero aceptable desde el punto de vista farmacéutico, donde, W es hidrógeno o halógeno; X es hidrógeno; alquilo C1-8 opcionalmente sustituido; hidroxilo; halógeno; tioéter; sulfinilo; sulfonilo; ciano; o C1-8 opcionalmente sustituido; Y es hidrógeno; alquilo C1-8 opcionalmente sustituido; o halógeno; Z es hidrógeno; o alquilo C1-8; A es CH o N; B es CH o N, siempre que al menos uno de A o B sea N, y que cuando A sea N, B sea CH; R1 es hidroxilo; alquilo C1-8 opcionalmente sustituido, alquenilo C2-8; alquinilo C2-8; heterociclilo opcionalmente sustituido; heteroarilo opcionalmente sustituido; o arilo opcionalmente sustituido; R2 es hidrógeno; hidroxilo; halógeno; heteroarilo opcionalmente sustituido; alquilo C1-8 opcionalmente sustituido; -C(O)-Rc; -C(O)O-Rd; -C(O)C(O)-NH-Rd; -C(O)C(O)-O-Rd; -C(O)-N(RdRd); -C(S)-N(RdRd); -C(S)-O-Re; -S(O2)Re; -C(NRe)-S-Re; o -C(S)-S-Rf; Rc es hidrógeno; amino opcionalmente sustituido; arilo opcionalmente sustituido; C(O)-Rn; heterociclilo opcionalmente sustituido; heteroarilo; tiazolamino; alquilo C1-8 opcionalmente sustituido; cicloalquilo; o alquenilo C2-8 opcionalmente sustituido; Rd es en cada aparición independientemente hidrógeno; alquenilo C2-8; alquinilo C2-8; arilo opcionalmente sustituido; cicloalquilo; o alquilo C1-8 opcionalmente sustituido; Re es hidrógeno; alquilo C1-8 opcionalmente sustituido; cicloalquilo opcionalmente sustituido; o arilo opcionalmente sustituido; Rf es alquilo C1-8 opcionalmente sustituido; Rn es hidroxilo; alcoxi C1-8; amino; arilo opcionalmente sustituido; R3 es hidrógeno; o -C(O)-Rg; y Rg es hidroxilo; amino opcionalmente sustituido; heteroarilo opcionalmente sustituido; o heterociclilo opcionalmente sustituido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34918610P | 2010-05-27 | 2010-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR081261A1 true AR081261A1 (es) | 2012-07-18 |
Family
ID=45004375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110101835A AR081261A1 (es) | 2010-05-27 | 2011-05-27 | Metodos para tratar afecciones virales |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20130171103A1 (es) |
| AR (1) | AR081261A1 (es) |
| TW (1) | TW201141864A (es) |
| WO (1) | WO2011150162A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3184380A1 (en) * | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating cancer and non-neoplastic conditions |
| MX388871B (es) | 2014-06-27 | 2025-03-20 | Nogra Pharma Ltd | Moduladores del receptor arilo y metodos para elaborar y usar los mismos. |
| WO2016030863A1 (en) | 2014-08-29 | 2016-03-03 | Glaxosmithkline Intellectual Property Development Limited | Compounds and methods for treating viral infections |
| WO2016069949A1 (en) * | 2014-10-29 | 2016-05-06 | Virginia Tech Intellectual Properties, Inc. | Compositions and formulations of methylerthritol phosphate pathway inhibitors and uses thereof |
| KR20250044939A (ko) | 2014-12-18 | 2025-04-01 | 에프. 호프만-라 로슈 아게 | 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도 |
| US20180098972A1 (en) | 2015-01-26 | 2018-04-12 | Children's Medical Center Corporation | Treatment of infectious diseases |
| US20180002344A1 (en) | 2016-06-16 | 2018-01-04 | Genentech, Inc. | Heteroaryl estrogen receptor modulators and uses thereof |
| KR20200035292A (ko) | 2017-08-01 | 2020-04-02 | 피티씨 테라퓨틱스, 인크. | 혈액 암 치료에 사용하기 위한 dhodh 억제제 |
| CN109867662B (zh) * | 2018-02-07 | 2020-08-14 | 南方医科大学 | 一种咔唑β-氨基醇类衍生物及其制备方法和用途 |
| JP6916969B1 (ja) | 2018-06-21 | 2021-08-11 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ３−（（１Ｒ，３Ｒ）−１−（２，６−ジフルオロ−４−（（１−（３−フルオロプロピル）アゼチジン−３−イル）アミノ）フェニル）−３−メチル−１，３，４，９−テトラヒドロ−２Ｈ−ピリド［３，４−ｂ］インドール−２−イル）−２，２−ジフルオロプロパン−１−オールの固体形態及び置換されたフェニル又はピリジニル部分を含む縮合三環式化合物を調製するための方法とそれらの使用方法 |
| EP3980015A4 (en) * | 2019-06-06 | 2024-02-21 | University of Maryland, Baltimore | BROAD-SPECTRUM ANTIVIRAL COMPOUNDS TARGETING THE SKI COMPLEX |
| WO2021213946A1 (en) * | 2020-04-19 | 2021-10-28 | Englmeier Ludwig | Prophylaxis and treatment of coronavirus infection |
| EP4146203A4 (en) * | 2020-05-08 | 2024-05-29 | PTC Therapeutics, Inc. | DHODH INHIBITOR FOR THE TREATMENT OF COVID-19 |
| US20250090557A1 (en) * | 2020-07-11 | 2025-03-20 | The Regents Of The University Of California | Compositions and Methods for Inhibiting and Treating Coronavirus Infections |
| JP2024502270A (ja) | 2020-12-23 | 2024-01-18 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | エストロゲン受容体調節薬 |
| CN114159434B (zh) * | 2021-11-04 | 2023-06-20 | 中山亿维迪科技有限公司 | 一种含氮多环类芳香化合物在制备抗疱疹病毒药物中的应用 |
| CR20240264A (es) * | 2021-12-31 | 2024-09-03 | Ptc Therapeutics Inc | Compuestos de carbolina y uso de los mismos |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7767689B2 (en) * | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
| WO2007002051A1 (en) * | 2005-06-22 | 2007-01-04 | Smithkline Beecham Corporation | Carboline derivatives and their use as inhibitors of flaviviridae infections |
| JP2009526070A (ja) * | 2006-02-09 | 2009-07-16 | シェーリング コーポレイション | Ｈｃｖプロテアーゼ阻害薬とｈｃｖポリメラーゼ阻害薬との組み合わせ、ならびにそれらに関連する処置の方法 |
-
2011
- 2011-05-26 US US13/699,849 patent/US20130171103A1/en not_active Abandoned
- 2011-05-26 WO PCT/US2011/038067 patent/WO2011150162A1/en not_active Ceased
- 2011-05-27 TW TW100118779A patent/TW201141864A/zh unknown
- 2011-05-27 AR ARP110101835A patent/AR081261A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011150162A1 (en) | 2011-12-01 |
| TW201141864A (en) | 2011-12-01 |
| US20130171103A1 (en) | 2013-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR081261A1 (es) | Metodos para tratar afecciones virales | |
| EA201891876A1 (ru) | Тетрациклические пиридоновые соединения в качестве противовирусных средств | |
| PE20180232A1 (es) | Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue | |
| EA201890735A1 (ru) | Модуляторы корового белка вируса гепатита b | |
| UY37133A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| EA201591328A1 (ru) | Замещенные гетероциклом тетрациклические соединения и способы их применения для лечения вирусных заболеваний | |
| BR112015021027A8 (pt) | compostos terapêuticos, seus usos, e composições farmacêuticas | |
| AR095034A1 (es) | El uso de los agonistas del receptor 2 del péptido formilo para el tratamiento de las enfermedades inflamatorias oculares | |
| EA201491548A1 (ru) | 2'-замещенные карбануклеозидные аналоги для противовирусного лечения | |
| CR20140086A (es) | Tratamientos de combinación para hepatitis c | |
| CO2019010295A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| DOP2015000240A (es) | 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante | |
| EA201692506A3 (ru) | Ингибиторы репликации вирусов гриппа | |
| AR108046A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| CO2019013042A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112015025766A2 (pt) | derivado de nucleosídeo altamente ativo para o tratamento de hcv | |
| BR112012000287B8 (pt) | composição farmacêutica para um inibidor de protease viral de hepatite c | |
| CO2019010292A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| AR085327A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR099632A1 (es) | Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos | |
| CO2019012035A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| EA201892216A1 (ru) | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге | |
| BR112015024552A2 (pt) | compostos de fórmula (a), composição farmacêutica, métodos para a preparação do composto e métodos de tratamento ou prevenção de infecções | |
| RU2013150861A (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний | |
| EA201490213A1 (ru) | Бензофурановые соединения для лечения инфекций вирусом гепатита с |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |